Rapt Therapeutics Inc (RAPT)

$9.73 +0.17 (1.78%)
Market Cap 158.08M
Revenue (ttm) 0.00
Net Income (ttm) -129.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 120,300
Avg Vol 110,558
Day's Range N/A - N/A
Shares Out 16.54M
Stochastic %K 99%
Beta -0.11
Analysts Sell
Price Target $30.00

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its l...

Industry: Biotechnology
Sector: Healthcare
Phone: 650-489-9000
Address:
561 Eccles Avenue, South San Francisco, United States
StockScanners
StockScanners Jun. 27 at 1:10 AM
$RAPT Reached 9.75, keep watch
0 · Reply
Zipcash
Zipcash Jun. 26 at 11:28 PM
$RAPT breaking $15.00 next week
0 · Reply
BayAreaBiotech
BayAreaBiotech Jun. 26 at 8:06 PM
$RAPT Do you guys think we will get some news regarding the next-gen CCR4 antagonist by tomorrow or Monday, if the company stays true to their words to release CCR4 next-gen updates in the first half of 2025?
3 · Reply
Breqqswings
Breqqswings Jun. 26 at 7:38 PM
$RAPT getting 🥵
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 1:17 PM
$RAPT
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 10:34 AM
$RAPT zero???
0 · Reply
StockScanners
StockScanners Jun. 26 at 12:36 AM
$RAPT Keep watch if this holds above 8.75
0 · Reply
SteveStachion
SteveStachion Jun. 25 at 11:16 PM
$RAPT think this will be a daily climber
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 7:31 PM
$RAPT following closely 👀👀
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 25 at 7:15 PM
$RAPT flying AH?
0 · Reply
Latest News on RAPT
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Jun 23, 2025, 8:00 AM EDT - 3 days ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

Jun 13, 2025, 9:00 AM EDT - 13 days ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

RAPT Therapeutics to Participate in Upcoming Investor Conferences

Jun 4, 2025, 4:05 PM EDT - 22 days ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025, 8:00 AM EDT - 7 weeks ago

RAPT Therapeutics Reports First Quarter 2025 Financial Results

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

Apr 15, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 8:00 AM EST - 4 months ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 6 months ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

Jan 6, 2025, 8:00 AM EST - 6 months ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

RAPT Therapeutics Announces $150 Million Private Placement

Dec 23, 2024, 7:10 AM EST - 6 months ago

RAPT Therapeutics Announces $150 Million Private Placement

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

Nov 11, 2024, 10:34 AM EST - 8 months ago

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24, 2024, 6:32 PM EDT - 1 year ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

May 21, 2024, 8:39 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX RENB SAGE TMCI

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20, 2024, 4:35 AM EDT - 1 year ago

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

RAPT Therapeutics Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Apr 9, 2024, 12:00 PM EDT - 1 year ago

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

VKTX, JANX and these biotech stocks are surging in 2024

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX MCRB RVNC

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 26, 2024, 4:00 AM EST - 1 year ago

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

Feb 20, 2024, 8:36 AM EST - 1 year ago

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:41 AM EST - 1 year ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

Feb 20, 2024, 7:30 AM EST - 1 year ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Feb 13, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Nov 27, 2023, 8:00 AM EST - 1 year ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

Nov 3, 2023, 12:00 PM EDT - 1 year ago

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

Nov 1, 2023, 4:05 PM EDT - 1 year ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Oct 18, 2023, 9:00 AM EDT - 1 year ago

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

Aug 30, 2023, 4:05 PM EDT - 1 year ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Aug 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 13, 2023, 3:59 PM EDT - 2 years ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

Jun 7, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

May 25, 2023, 5:00 PM EDT - 2 years ago

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

May 3, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 4:19 PM EDT - 2 years ago

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

RAPT Therapeutics: Potential Strong Upside Ahead

Mar 30, 2023, 12:12 AM EDT - 2 years ago

RAPT Therapeutics: Potential Strong Upside Ahead

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

Mar 29, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

Mar 14, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Feb 7, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

Dec 8, 2022, 6:30 AM EST - 2 years ago

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

Nov 30, 2022, 7:05 PM EST - 2 years ago

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 17, 2022, 9:38 PM EST - 2 years ago

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Nov 17, 2022, 4:24 PM EST - 2 years ago

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

RAPT Therapeutics Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2022 Financial Results

StockScanners
StockScanners Jun. 27 at 1:10 AM
$RAPT Reached 9.75, keep watch
0 · Reply
Zipcash
Zipcash Jun. 26 at 11:28 PM
$RAPT breaking $15.00 next week
0 · Reply
BayAreaBiotech
BayAreaBiotech Jun. 26 at 8:06 PM
$RAPT Do you guys think we will get some news regarding the next-gen CCR4 antagonist by tomorrow or Monday, if the company stays true to their words to release CCR4 next-gen updates in the first half of 2025?
3 · Reply
Breqqswings
Breqqswings Jun. 26 at 7:38 PM
$RAPT getting 🥵
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 1:17 PM
$RAPT
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 10:34 AM
$RAPT zero???
0 · Reply
StockScanners
StockScanners Jun. 26 at 12:36 AM
$RAPT Keep watch if this holds above 8.75
0 · Reply
SteveStachion
SteveStachion Jun. 25 at 11:16 PM
$RAPT think this will be a daily climber
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 7:31 PM
$RAPT following closely 👀👀
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 25 at 7:15 PM
$RAPT flying AH?
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 6:54 PM
$RAPT can’t say you weren’t warned.. 🚨🚨..
0 · Reply
Ianwalsh15
Ianwalsh15 Jun. 25 at 6:35 PM
$RAPT did this reverse split? Sorry haven’t been paying attention
1 · Reply
Breqqswings
Breqqswings Jun. 25 at 6:35 PM
$RAPT
0 · Reply
SteveStachion
SteveStachion Jun. 25 at 6:25 PM
$RAPT 99.42 %held by tutes...thats beyond interesting.. short shares available going up and a low ctb..seems there r mixed reviews on high tute ownership, could be short sales already on lend..does not seem extraordinary tho atm.. could this be lending itself to something else going on with the company? Lots of changes recently, an legit input appreciated. Change on board with veterans, could this be a merger of sorts ahead for the company?? https://www.stocktitan.net/news/RAPT/rapt-therapeutics-names-two-industry-veterans-to-its-board-of-2rfnh17zc71w.html
0 · Reply
Zipcash
Zipcash Jun. 25 at 6:10 PM
$RAPT $20.00 is coming up next . Added and holding for mega gains.
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 25 at 5:58 PM
$RAPT Discover why RAPT Therapeutics could be the next biotech breakout, fueled by promising anti-IgE data, and strong cash reserves. https://biotechhealthx.com/biotech-news/rapt-therapeutics-rapt-poised-for-massive-breakout-after-reverse-split-and-clinical-wins/
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 25 at 5:41 PM
$RAPT squeezing…???
0 · Reply
Skywalker86
Skywalker86 Jun. 25 at 5:32 PM
$NKTR 👉 $RAPT tying to be sneaky. Sympathy play to $NKTR 🤔
0 · Reply
Breqqswings
Breqqswings Jun. 25 at 5:28 PM
$NKTR $RAPT
0 · Reply
Breqqswings
Breqqswings Jun. 25 at 3:22 PM
$RAPT after seeing $NKTR and with RAPT having a 97% short I’m pushing all my chips in on this one.
0 · Reply
BayAreaBiotech
BayAreaBiotech Jun. 24 at 8:08 PM
$RAPT RAPT is expected to announce the pivot to next-gen CCR4 antagonist compound soon. They aimed to develop CCR4 antagonists with improved safety profiles and to nominate a new candidate by the first half of 2025, which is literally end of this week. Clear preclinical toxicology data demonstrating a safe margin for liver function would directly address zelnecirnon’s past liver toxicity. If released, this would build confidence in the next-generation molecule and propel the stock price upward. The price movement was decent today. Let’s see what transpires this week.
2 · Reply
stockanalysis_
stockanalysis_ Jun. 21 at 6:20 PM
Most Shorted Stocks: $ALZN $RAPT $NKTR $TSAT $VLDR View the entire list here: https://stockanalysis.com/list/most-shorted-stocks/?ref=saveontrading
0 · Reply